Misuse of blood thinners in dialysis patients reported

NewsGuard 100/100 Score

Reuters/ABC News reports on research published in the Journal of the American Medical Association that examined the misuse of two blood thinners - Lovenox and Integrilin - in "about 20 percent of kidney dialysis patients who undergo a procedure to open a blocked artery [who] are given the wrong blood clot medicine, increasing the chances of significant bleeding, researchers said Tuesday. They said the findings suggest many doctors in the United States ignore warnings on drug labels, often putting patients at risk of serious harm or death."  The two drugs "are not recommended for use in kidney dialysis patients" (Wilson, 12/8).

U.S. News and World Report/HealthDay: "According to [study author Dr. Thomas] Tsai, this particular type of medicating error may stem from the simple fact that there are so many possible medications for physicians to choose from now. ... Ease of use and convenience may also play a role in doctors' turning to these particular drugs, Tsai said. Meanwhile, the population of people undergoing dialysis is also exploding, and is projected to pass the 2 million mark worldwide by 2010, according to the study" (Gardner, 12/8).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New RNA therapy zilebesiran shows promise in lowering blood pressure